Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
---|
03/10/2004 | CN1480139A Local medical compsn contg cholinergic medicine or calcium passage retardant |
03/10/2004 | CN1480134A Combination of iodine amino acid as well as its preparation method and application |
03/10/2004 | CN1480129A Ground substance and plaster of Chinese traditional medicine as well as its preparing method |
03/10/2004 | CN1480128A Preparation of transparent, cryptomorphic external remedy |
03/10/2004 | CN1141297C Process for preparing amlodiping benzenesulphonate |
03/09/2004 | US6703488 Use for intracellular delivery of drugs or other agents for diagnosis and therapy of malignancies or immune-mediated or inflammatory conditions providing rapid, efficient internal-ization of the cytokine receptor antibody/antigen complexes |
03/09/2004 | US6703482 Isolated from three phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins comprising sh3 and glutathione s-transferase (gst). |
03/09/2004 | US6703424 Dispersible compositions containing L-DOPA ethyl ester |
03/09/2004 | US6703417 Improved bioavailability; anticarcinogenic |
03/09/2004 | US6703381 Administering amphiphilic enkephalin-oligomer conjugate |
03/09/2004 | US6703371 Preparations for reducing oxygen consumption during physical efforts |
03/09/2004 | US6703369 Lipase inhibiting compositions |
03/09/2004 | US6703365 Glucagon-like insulinotropic peptides, compositions and methods |
03/09/2004 | US6703050 Methods and compositions for the prevention or treatment of cancer |
03/09/2004 | US6703047 Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
03/09/2004 | US6703046 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
03/09/2004 | US6703040 Polymer impregnated with bactericide, bacteriphage or antibiotic |
03/09/2004 | US6703039 Reversible gelling system for ocular drug delivery |
03/09/2004 | US6703037 Biodegradable macromers for the controlled release of biologically active substances |
03/09/2004 | US6703030 Comprising a carboxylated, acidic amino acid obtained by acidifying an acidic amino acid with a carboxylic acid and a carrier; nonirritating |
03/09/2004 | US6703029 Finely dispersed emulsifier-free systems of the oil-in-water and water-in-oil type |
03/09/2004 | US6703020 Antibody conjugate methods for selectively inhibiting VEGF |
03/09/2004 | US6702997 Premeasured single unit dose; may be free of anti-microbial preservatives, such as benzalkonium chloride. |
03/09/2004 | US6702995 Delivery system |
03/09/2004 | CA2408198C Pharmaceutical composition comprising cefuroxime axetil |
03/09/2004 | CA2268868C Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
03/09/2004 | CA2260992C Eye treatments using synthetic thyroid hormone compositions |
03/09/2004 | CA2052229C Antifungal composition in a dry powdered spray form |
03/04/2004 | WO2004018681A2 Il-7 drug substance, il- 7 comprising composition, preparation and uses thereof |
03/04/2004 | WO2004018519A2 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
03/04/2004 | WO2004018511A2 Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins |
03/04/2004 | WO2004018468A2 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
03/04/2004 | WO2004018444A1 Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparations and the use there of |
03/04/2004 | WO2004018360A1 Methods and compounds for controlling the morphology and shrinkage of silica derived from polyol-modified silanes |
03/04/2004 | WO2004018312A1 Injectable pharmaceutical suspension in a two-chamber vial |
03/04/2004 | WO2004018066A2 Aqueous two-phase systems for particle manipulation and encapsulation within microscopic volumes |
03/04/2004 | WO2004018025A1 Pharmaceutical compositions |
03/04/2004 | WO2004018010A2 Methods of drug delivery using sulphated chitinous polymers |
03/04/2004 | WO2004018001A1 Polyamine conjugates with acidic retinoids and preparation thereof |
03/04/2004 | WO2004018000A2 Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents |
03/04/2004 | WO2004017999A1 Non-glycosylated polyacrylamide conjugates and their use for cytoprotection |
03/04/2004 | WO2004017998A2 Topical emulsion- gel composition comprising diclofenac sodium |
03/04/2004 | WO2004017975A1 Stable aqueous solutions of risperidone and methods for their preparation |
03/04/2004 | WO2004017962A2 Tropical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region |
03/04/2004 | WO2004017943A2 Non-vesicular cationic lipid formulations |
03/04/2004 | WO2004017937A1 Biodegradable composition with prolonged release of the biological active compound and preparation thereof |
03/04/2004 | WO2004017914A2 Inhalation composition |
03/04/2004 | WO2004017907A2 Blood clot-targeted nanoparticles |
03/04/2004 | WO2004017904A2 Corticosteroid conjugates and uses thereof |
03/04/2004 | WO2004017903A2 Methods for treating fungal infections |
03/04/2004 | WO2004017897A2 Aripiprazole complex formulation and method |
03/04/2004 | WO2004017895A2 Formaldehyde-ammonium salt complexes for the stabilization of blood cells |
03/04/2004 | WO2004017810A2 Tumor specific oligosaccharide epitopes and use thereof |
03/04/2004 | WO2003105908A9 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
03/04/2004 | WO2003101427A8 Immunoliposomes formed with aggregated antibody |
03/04/2004 | WO2003079993A3 hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION |
03/04/2004 | WO2003072143A9 Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
03/04/2004 | WO2003070755A3 Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier |
03/04/2004 | WO2003062372A3 Nanoparticle assembled hollow spheres |
03/04/2004 | WO2003060076A3 Povidone-containing carriers for polypeptide growth factors |
03/04/2004 | WO2003057716A3 Dendritic encapsulation of active agents |
03/04/2004 | WO2003055442A3 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
03/04/2004 | WO2003053463A3 Poxvirus-containing compositions and process for their preparation |
03/04/2004 | WO2003051286A3 Hydrogel compositions, devices, and microscale components |
03/04/2004 | WO2003048207A3 Anti-dota antibody |
03/04/2004 | WO2003043574A3 Pharmaceutical compositions in particulate form |
03/04/2004 | WO2003039225A3 Antigen arrays comprising rankl for treatment of bone disease |
03/04/2004 | WO2003033025A3 Cyclodextrin complexes |
03/04/2004 | WO2003032904A3 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
03/04/2004 | WO2003026629A3 Modified release dosage forms |
03/04/2004 | WO2003026581A3 Pharmaceutical compositions and methods for treating cancer |
03/04/2004 | WO2003015759A3 Treatment of hyperproliferative conditions of body surfaces |
03/04/2004 | WO2003005961A3 A controlled release biodegradable gel matrix |
03/04/2004 | WO2003002243A3 Method and device for electrochemical formation of therapeutic species in vivo |
03/04/2004 | WO2003002136A3 Stable formulation of modified glp-1 |
03/04/2004 | WO2002085248A3 Prostanoids augment ocular drug penetration |
03/04/2004 | WO2002078623A3 Uses of targeted oxidative therapeutic formulation in arteriosclerosis |
03/04/2004 | WO2002072606A3 Epitope testing using hla |
03/04/2004 | WO2002047664A8 Microparticles with an improved release profile and method for the production thereof |
03/04/2004 | WO2002022134A8 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
03/04/2004 | WO2002020762A8 Tnf receptor-like molecules and uses thereof |
03/04/2004 | WO2002015938A8 Testosterone ester formulation for human use |
03/04/2004 | US20040044408 Cell-culture and polymer constructs |
03/04/2004 | US20040044241 Novel succinate salt of O-desmethyl-venlafaxine |
03/04/2004 | US20040044178 Hepatotropic conjugates of antiblastic drugs accomplishing a loco-regional chemotherapy of liver micrometastases after adminstration by peripheral venous route |
03/04/2004 | US20040044125 Therapeutic AZO-compounds for drug delivery |
03/04/2004 | US20040044086 Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism |
03/04/2004 | US20040044076 Neutrophil imaging methods in cystic fibrosis |
03/04/2004 | US20040044070 Cardiovascular disorders; antiarrhythmia agents |
03/04/2004 | US20040044035 Antiallergens; rhinitis |
03/04/2004 | US20040044018 Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor |
03/04/2004 | US20040043980 Bactericides; storage stability |
03/04/2004 | US20040043964 Cellulosic particle for pharmaceuticals preparation |
03/04/2004 | US20040043963 Complex of chitosan, conjugated linoleic acid, vitamin a and cyclodextrin |
03/04/2004 | US20040043952 Complex of lipid and pentaerythritol; supplying nucleic acids to cells; transfection cells; drug delivery |
03/04/2004 | US20040043949 Therapeutic system targeting pathogen proteases and uses thereof |
03/04/2004 | US20040043939 Peptide-based gemini compounds |
03/04/2004 | US20040043933 Mixture with pH moderator, antioxidant and Group 2a salt; anticoagulant |
03/04/2004 | US20040043927 Wound healing agents; anticancer agents; cardiovascular disorders |
03/04/2004 | US20040043925 Cyclic depsipeptides; veterinary medicine |